Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
SS-31
EfficacyHigh
Studies8
Participants750
StatusAvailable

SS-31

Elamipretide (D-Arg-Dmt-Lys-Phe-NH2)

SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane to optimize mitochondrial structure and function. Originally developed for mitochondrial diseases and heart failure, SS-31 enhances cellular energy production and reduces oxidative stress across multiple organ systems. It has shown promise in clinical trials for heart failure with preserved ejection fraction, Barth syndrome, and mitochondrial myopathies.

Clinical Benefits

Targets mitochondria through cardiolipin binding
Enhances cellular ATP production and energy metabolism
Reduces oxidative stress and mitochondrial ROS
Improves heart function in heart failure patients
Enhances exercise capacity and 6-minute walk distance
Shows benefits in rare mitochondrial genetic disorders

Mechanism of Action

SS-31 is a mitochondria-targeting tetrapeptide that selectively binds to cardiolipin, a unique phospholipid component of the inner mitochondrial membrane. This binding optimizes the structure and function of cardiolipin, which is essential for proper electron transport chain activity and mitochondrial cristae structure. By stabilizing cardiolipin, SS-31 reduces reactive oxygen species (ROS) production, enhances ATP synthesis, and improves overall mitochondrial bioenergetics across multiple cell types.

Key Action:

Proven Results

95%
Maximum Weight Loss
Clinical research data
28%
Diabetes Risk Reduction
Clinical research data
750
Total Participants
Research studies
35%
CV Risk Reduction
Clinical data

Medical Disclaimer

SS-31 (Elamipretide) is currently in Phase III clinical trials and is not yet FDA approved for general clinical use. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all investigational uses.